Rosiglitazone use and associated adverse event rates in Canada: an updated analysis

BACKGROUND: We previously reported on the change in the use of rosiglitazone-containing products (RCP) and adverse event reporting rates in Canadian patients between 2004 and 2010. The present study extends this analysis to include the January 2011 to December 2012 time period. METHODS: RCP utilizat...

Descripción completa

Detalles Bibliográficos
Autores principales: Iczkovitz, Sandra, Dhalla, Daniella, Terres, Jorge A. Ross
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4588901/
https://www.ncbi.nlm.nih.gov/pubmed/26419903
http://dx.doi.org/10.1186/s13104-015-1448-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4588901/
https://www.ncbi.nlm.nih.gov/pubmed/26419903
http://dx.doi.org/10.1186/s13104-015-1448-6

Ejemplares similares